Is Spotify a Millionaire-Maker Stock?
Spotify (NYSE:SPOT) may seem like an expensive proposition trading closer…
Sell
22
SBFM Quote, Financials, Valuation and Earnings
Last price:
$1.22
Seasonality move
:
101.98%
Day range:
$1.21 - $1.28
52-week range:
$1.17 - $23.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.04x
P/B ratio:
0.19x
Volume:
100.2K
Avg. volume:
2.9M
1-year change:
-93.15%
Market cap:
$4.5M
Revenue:
$34.9M
EPS (TTM):
-$155.33
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SBFM
Sunshine Biopharma
|
$12.5M | -- | 62.76% | -- | -- |
|
DSGN
Design Therapeutics
|
-- | -$0.28 | -- | -40% | $7.33 |
|
NBY
NovaBay Pharmaceuticals
|
$3M | -$0.24 | 14.03% | -95.43% | $0.85 |
|
NNVC
Nanoviricides
|
-- | -$0.20 | -- | -26.67% | -- |
|
OGEN
Oragenics
|
-- | -- | -- | -- | $1.00 |
|
TOVX
Theriva Biologics
|
-- | -$5.50 | -- | -8.25% | $6.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SBFM
Sunshine Biopharma
|
$1.25 | -- | $4.5M | -- | $0.00 | 0% | 0.04x |
|
DSGN
Design Therapeutics
|
$3.50 | $7.33 | $198.7M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals
|
$0.56 | $0.85 | $3.3M | -- | $0.00 | 0% | 0.15x |
|
NNVC
Nanoviricides
|
$1.32 | -- | $20.6M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics
|
$0.17 | $1.00 | $3.6M | -- | $0.00 | 0% | 1.05x |
|
TOVX
Theriva Biologics
|
$0.53 | $6.00 | $1.5M | -- | $0.00 | 0% | 0.63x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SBFM
Sunshine Biopharma
|
-- | -0.425 | -- | 3.41x |
|
DSGN
Design Therapeutics
|
-- | 1.264 | -- | -- |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | -0.186 | 1.51% | 0.75x |
|
NNVC
Nanoviricides
|
-- | 2.080 | -- | -- |
|
OGEN
Oragenics
|
-- | 3.254 | -- | -- |
|
TOVX
Theriva Biologics
|
-- | -2.512 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SBFM
Sunshine Biopharma
|
$2.9M | -$1.1M | -18.13% | -18.13% | -11.65% | -$2M |
|
DSGN
Design Therapeutics
|
-- | -$16.7M | -- | -- | -- | -$9.9M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$1.1M | -334.47% | -461.38% | -44% | -$2.1M |
|
NNVC
Nanoviricides
|
-- | -$2.1M | -- | -- | -- | -$2.2M |
|
OGEN
Oragenics
|
-- | -$3.4M | -- | -- | -- | -$2M |
|
TOVX
Theriva Biologics
|
-- | -$4.6M | -- | -- | -- | -$4.7M |
Sunshine Biopharma vs. Competitors
-
Which has Higher Returns SBFM or DSGN?
Design Therapeutics has a net margin of -14.2% compared to Sunshine Biopharma's net margin of --. Sunshine Biopharma's return on equity of -18.13% beat Design Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SBFMSunshine Biopharma33.98% -$0.94 $25M DSGNDesign Therapeutics-- -$0.24 -- -
What do Analysts Say About SBFM or DSGN?
Sunshine Biopharma has a consensus price target of --, signalling upside risk potential of 23900%. On the other hand Design Therapeutics has an analysts' consensus of $7.33 which suggests that it could grow by 109.52%. Given that Sunshine Biopharma has higher upside potential than Design Therapeutics, analysts believe Sunshine Biopharma is more attractive than Design Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings SBFMSunshine Biopharma0 0 0 DSGNDesign Therapeutics0 2 0 -
Is SBFM or DSGN More Risky?
Sunshine Biopharma has a beta of 2.609, which suggesting that the stock is 160.921% more volatile than S&P 500. In comparison Design Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SBFM or DSGN?
Sunshine Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Design Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sunshine Biopharma pays -- of its earnings as a dividend. Design Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SBFM or DSGN?
Sunshine Biopharma quarterly revenues are $8.4M, which are larger than Design Therapeutics quarterly revenues of --. Sunshine Biopharma's net income of -$1.2M is higher than Design Therapeutics's net income of -$13.7M. Notably, Sunshine Biopharma's price-to-earnings ratio is -- while Design Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sunshine Biopharma is 0.04x versus -- for Design Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SBFMSunshine Biopharma0.04x -- $8.4M -$1.2M DSGNDesign Therapeutics-- -- -- -$13.7M
-
Which has Higher Returns SBFM or NBY?
NovaBay Pharmaceuticals has a net margin of -14.2% compared to Sunshine Biopharma's net margin of -49.65%. Sunshine Biopharma's return on equity of -18.13% beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital SBFMSunshine Biopharma33.98% -$0.94 $25M NBYNovaBay Pharmaceuticals65.26% -$0.60 $1.1M -
What do Analysts Say About SBFM or NBY?
Sunshine Biopharma has a consensus price target of --, signalling upside risk potential of 23900%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 50.71%. Given that Sunshine Biopharma has higher upside potential than NovaBay Pharmaceuticals, analysts believe Sunshine Biopharma is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings SBFMSunshine Biopharma0 0 0 NBYNovaBay Pharmaceuticals1 0 0 -
Is SBFM or NBY More Risky?
Sunshine Biopharma has a beta of 2.609, which suggesting that the stock is 160.921% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.
-
Which is a Better Dividend Stock SBFM or NBY?
Sunshine Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sunshine Biopharma pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SBFM or NBY?
Sunshine Biopharma quarterly revenues are $8.4M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Sunshine Biopharma's net income of -$1.2M is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Sunshine Biopharma's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sunshine Biopharma is 0.04x versus 0.15x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SBFMSunshine Biopharma0.04x -- $8.4M -$1.2M NBYNovaBay Pharmaceuticals0.15x -- $2.4M -$1.2M
-
Which has Higher Returns SBFM or NNVC?
Nanoviricides has a net margin of -14.2% compared to Sunshine Biopharma's net margin of --. Sunshine Biopharma's return on equity of -18.13% beat Nanoviricides's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SBFMSunshine Biopharma33.98% -$0.94 $25M NNVCNanoviricides-- -$0.14 -- -
What do Analysts Say About SBFM or NNVC?
Sunshine Biopharma has a consensus price target of --, signalling upside risk potential of 23900%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 392.42%. Given that Sunshine Biopharma has higher upside potential than Nanoviricides, analysts believe Sunshine Biopharma is more attractive than Nanoviricides.
Company Buy Ratings Hold Ratings Sell Ratings SBFMSunshine Biopharma0 0 0 NNVCNanoviricides0 0 0 -
Is SBFM or NNVC More Risky?
Sunshine Biopharma has a beta of 2.609, which suggesting that the stock is 160.921% more volatile than S&P 500. In comparison Nanoviricides has a beta of 0.947, suggesting its less volatile than the S&P 500 by 5.32%.
-
Which is a Better Dividend Stock SBFM or NNVC?
Sunshine Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sunshine Biopharma pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SBFM or NNVC?
Sunshine Biopharma quarterly revenues are $8.4M, which are larger than Nanoviricides quarterly revenues of --. Sunshine Biopharma's net income of -$1.2M is higher than Nanoviricides's net income of -$2M. Notably, Sunshine Biopharma's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sunshine Biopharma is 0.04x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SBFMSunshine Biopharma0.04x -- $8.4M -$1.2M NNVCNanoviricides-- -- -- -$2M
-
Which has Higher Returns SBFM or OGEN?
Oragenics has a net margin of -14.2% compared to Sunshine Biopharma's net margin of --. Sunshine Biopharma's return on equity of -18.13% beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SBFMSunshine Biopharma33.98% -$0.94 $25M OGENOragenics-- -$0.27 -- -
What do Analysts Say About SBFM or OGEN?
Sunshine Biopharma has a consensus price target of --, signalling upside risk potential of 23900%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 493.12%. Given that Sunshine Biopharma has higher upside potential than Oragenics, analysts believe Sunshine Biopharma is more attractive than Oragenics.
Company Buy Ratings Hold Ratings Sell Ratings SBFMSunshine Biopharma0 0 0 OGENOragenics0 1 0 -
Is SBFM or OGEN More Risky?
Sunshine Biopharma has a beta of 2.609, which suggesting that the stock is 160.921% more volatile than S&P 500. In comparison Oragenics has a beta of 1.161, suggesting its more volatile than the S&P 500 by 16.138%.
-
Which is a Better Dividend Stock SBFM or OGEN?
Sunshine Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sunshine Biopharma pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SBFM or OGEN?
Sunshine Biopharma quarterly revenues are $8.4M, which are larger than Oragenics quarterly revenues of --. Sunshine Biopharma's net income of -$1.2M is higher than Oragenics's net income of -$3.3M. Notably, Sunshine Biopharma's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sunshine Biopharma is 0.04x versus 1.05x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SBFMSunshine Biopharma0.04x -- $8.4M -$1.2M OGENOragenics1.05x -- -- -$3.3M
-
Which has Higher Returns SBFM or TOVX?
Theriva Biologics has a net margin of -14.2% compared to Sunshine Biopharma's net margin of --. Sunshine Biopharma's return on equity of -18.13% beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SBFMSunshine Biopharma33.98% -$0.94 $25M TOVXTheriva Biologics-- -$1.60 -- -
What do Analysts Say About SBFM or TOVX?
Sunshine Biopharma has a consensus price target of --, signalling upside risk potential of 23900%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 1032.29%. Given that Sunshine Biopharma has higher upside potential than Theriva Biologics, analysts believe Sunshine Biopharma is more attractive than Theriva Biologics.
Company Buy Ratings Hold Ratings Sell Ratings SBFMSunshine Biopharma0 0 0 TOVXTheriva Biologics1 1 0 -
Is SBFM or TOVX More Risky?
Sunshine Biopharma has a beta of 2.609, which suggesting that the stock is 160.921% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.
-
Which is a Better Dividend Stock SBFM or TOVX?
Sunshine Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sunshine Biopharma pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SBFM or TOVX?
Sunshine Biopharma quarterly revenues are $8.4M, which are larger than Theriva Biologics quarterly revenues of --. Sunshine Biopharma's net income of -$1.2M is higher than Theriva Biologics's net income of -$4.4M. Notably, Sunshine Biopharma's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sunshine Biopharma is 0.04x versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SBFMSunshine Biopharma0.04x -- $8.4M -$1.2M TOVXTheriva Biologics0.63x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Is a Millionaire-Maker Stock?
From time to time, investors will run across the term…
5 Investors to Follow Other Than Warren Buffett
There is no doubt that Warren Buffett is one of…
Stock Ideas
Buy
68
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 40x
Alerts
Buy
60
RGC alert for May 10
Regencell Bioscience Holdings [RGC] is up 79.25% over the past day.
Buy
97
NGVC alert for May 10
Natural Grocers by Vitamin Cottage [NGVC] is up 30.26% over the past day.
Sell
38
ONTO alert for May 10
Onto Innovation [ONTO] is down 30.17% over the past day.
